Lipid-lowering drug targets and Parkinson's disease: A sex-specific Mendelian randomization study.

ABSTRACT: Parkinson's disease (PD) affects millions of individuals worldwide, and it is the second most common late-onset neurodegenerative disorder. There is no cure and current treatments only alleviate symptoms. Modifiable risk factors have been explored as possible options for decreasing risk or developing drug targets to treat PD, including low-density lipoprotein cholesterol (LDL-C). There is evidence of sex differences for cholesterol levels as well as for PD risk. Genetic datasets of increasing size are permitting association analyses with increased power, including sex-stratified analyses. These association results empower Mendelian randomization (MR) studies, which, given certain assumptions, test whether there is a causal relationship between the risk factor and the outcome using genetic

SUBMITTER: Zhao Y 

PROVIDER: S-EPMC9477004 | biostudies-literature | 2022

REPOSITORIES: biostudies-literature